Aduhelm Market Report 2026
Epidemiology, Pipeline Analysis, Market Insights & Forecasts
Aduhelm Market Overview
• The Aduhelm market growth in the historic period has been driven by aging global population, lack of curative alzheimer treatments • Market expansion is supported by growth in alzheimer patient pool, demand for early intervention therapies • Growth Driver: Rising Alzheimer's Disease Prevalence Fueling Growth Of The Aduhelm Market • Market Trend: Self-Injectable Antibody Innovations Enhancing Convenience And Treatment Adherence In Neurodegenerative Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Aduhelm Market?
Aduhelm (aducanumab) is a prescription medication developed by Biogen and Eisai Co., Ltd. It is a monoclonal antibody designed to treat Alzheimer’s disease by targeting and reducing amyloid-beta plaques in the brain, which are believed to contribute to the progression of the disease. The main types of indications in aduhelm are mild cognitive impairment and mild dementia. Mild cognitive impairment (MCI) refers to a noticeable decline in cognitive abilities, such as memory, attention, and reasoning, that is greater than expected for a person's age but not severe enough to interfere significantly with daily life. It is distributed through hospitals and clinics and retail and specialty pharmacies for various end users, including adults and geriatrics.
What Is The Aduhelm Market Size and Share 2026?
The growth in the historic period can be attributed to aging global population, lack of curative alzheimer treatments, advances in amyloid research, rising dementia prevalence, increased neurological clinical trials.What Is The Aduhelm Market Growth Forecast?
The growth in the forecast period can be attributed to growth in alzheimer patient pool, demand for early intervention therapies, expansion of biomarker based diagnosis, increased healthcare spending on neurology, development of next generation monoclonal antibodies. Major trends in the forecast period include growing focus on disease modifying alzheimer therapies, rising use of monoclonal antibodies in neurology, increased investment in neurodegenerative research, emphasis on early alzheimer diagnosis, expansion of amyloid targeting treatments.
Global Aduhelm Market Segmentation
1) By Indication: Mild Cognitive Impairment, Mild Dementia 2) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies 3) By End User: Adult, GeriatricWhat Is The Driver Of The Aduhelm Market?
Increasing prevalence of Alzheimer's disease is expected to propel the growth of the aduhelm market going forward. Alzheimer's disease is a progressive neurodegenerative disorder characterized by the decline of cognitive functions such as memory, reasoning, and behavior. The prevalence of Alzheimer's disease is increasing for several interconnected reasons, mainly driven by demographic, medical, and societal factors. Aduhelm (aducanumab-avwa) is used to treat Alzheimer's disease by targeting and reducing amyloid-beta plaques in the brain, which are believed to contribute to the disease's progression. For instance, in May 2024, according to the Alzheimer Society, a UK-based organization that provides support for people affected by dementia, currently, an estimated 982,000 people in the UK are living with dementia, a figure projected to increase to 1.4 million by 2040. Therefore, increasing prevalence of Alzheimer's disease is driving the growth of the Aduhelm industry.Key Players In The Global Aduhelm Market
Major companies operating in the aduhelm market are Biogen Inc., Eisai Co. Ltd.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Aduhelm Market Trends and Insights
Major companies operating in the Aduhelm market are focusing on developing innovative products, such as self-injectable monoclonal antibody formulations to improve patient convenience and adherence. A self-injectable formulation allows patients to administer maintenance doses themselves using a prefilled pen or syringe, reducing dependence on hospital infusions. For instance, in 2025, Eisai and Biogen, a US- and Japan-based biopharmaceutical collaboration specializing in neurological therapies and antibody-based medicines, launched Leqembi Iqik (lecanemab self-injectable pen). Its key features include a patient-friendly prefilled pen for at-home administration, a dosing regimen designed for maintenance therapy, safety and tolerability data comparable to the IV version, and a design that minimizes needle anxiety for patients.What Are Latest Mergers And Acquisitions In The Aduhelm Market?
In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for $1.4 billion. With this acquisition, AbbVie aims to bolster its Alzheimer’s-disease pipeline by securing Aliada’s innovative blood-brain barrier delivery platform and its lead asset ALIA-1758. Aliada Therapeutics is a US-based biotech focused on developing central nervous system (CNS) therapies using its proprietary MODEL platform for enhanced brain delivery.
Regional Insights
North America was the largest region in the aduhelm market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.Need data for a specific geography? Request Regional Data
What Defines the Aduhelm Market?
The aduhelm market consists of sales of products including aducanumab-avwa, Aduhelm injection, donanemab, and Aricept. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Aduhelm Market Report 2026?
The aduhelm market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the aduhelm industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Aduhelm Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | - |
| Revenue Forecast In 2030 | - |
| Growth Rate | - |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Indication, Distribution Channel, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Biogen Inc., Eisai Co. Ltd. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |